DGX - Fulgent Genetics: COVID Is Our Business But There Is More

• Fulgent Genetics makes advanced genetics-based COVID testing kits and has a sophisticated gene sequencing platform.
• However, the market reaction to an important contract awarded by the CDC in March was rather subdued.
• This remains a highly competitive area, but the company exhibits better growth and profitability metrics.
• The stock price should experience a rise of at least 10% following the next earnings call in May as well as a temporary increase in infection rates.
• I start by exploring the reasons for which the biotech's technology is required despite the availability of vaccines.

For further details see: